Evofem Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2012
Net Income	50.52	52.98	-76.7	-205.19	-142.31	-80.03	Upgrade
Depreciation & Amortization	0.34	1.78	1.02	1.02	0.3	0.26	Upgrade
Share-Based Compensation	1.01	1.19	3.31	8.9	12.7	8.58	Upgrade
Other Operating Activities	-55.77	-64.92	1.96	48.6	24.48	16.09	Upgrade
Operating Cash Flow	-3.91	-8.97	-70.41	-146.67	-104.83	-55.1	Upgrade
Capital Expenditures	-0.02	-0	-0.34	-2.94	-2.25	-0.16	Upgrade
Acquisitions	0	0	0	0.25	0.25	0.25	Upgrade
Change in Investments	-	-	-	-	-8.48	-8.23	Upgrade
Other Investing Activities	-	-	-	-	16.72	0.03	Upgrade
Investing Cash Flow	-0.02	-0	-0.34	-2.69	6.23	-8.12	Upgrade
Common Stock Issued	0.23	0.29	57.55	81.53	107.97	78.36	Upgrade
Share Repurchases	0	0	-0.02	-0.33	-2.87	75.4	Upgrade
Other Financing Activities	2.85	4.49	5.57	8.83	43.39	75.12	Upgrade
Financing Cash Flow	3.08	4.78	63.14	90.69	154.23	78.08	Upgrade
Net Cash Flow	-0.85	-3.4	-8.81	-58.66	55.63	14.86	Upgrade
Free Cash Flow	-3.92	-8.97	-70.75	-149.61	-107.08	-55.26	Upgrade
Free Cash Flow Margin	-24.48%	-49.25%	-420.21%	-1814.73%	-24009.64%	-	Upgrade
Free Cash Flow Per Share	-0.13	-0.01	-150.53	-2137.23	-2677.07	-2763.05	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.